Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.8% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTNM
3376
Contineum Therapeutics
CTNM
$583M
| $57.2K | ﹤0.01% |
+14,404
| New | +$62.6K |
|
3377
PepGen
PEPG
$122M
| $56.9K | ﹤0.01% |
51,300
+6,000
| +13% | +$8.48K |
|
3378
CollPlant Biotechnologies
CLGN
$5.16M
| $56.6K | ﹤0.01% |
41,600
+31,300
| +304% | +$64.8K |
|
3379
Unicycive Therapeutics
UNCY
$137M
| $56.2K | ﹤0.01% |
+11,790
| New | +$72.9K |
|
|
OPI
3380
DELISTED
Office Properties Income Trust
OPI
| $55.5K | ﹤0.01% |
+224,501
| New | +$63.1K |
|
3381
GameSquare
GAME
$34.6M
| $55.1K | ﹤0.01% |
63,400
+36,300
| +134% | +$26.6K |
|
|
ICG
3382
Intchains Group
ICG
$49.5M
| $55K | ﹤0.01% |
+30,700
| New | +$62.2K |
|
3383
PharmaCyte Biotech
PMCB
$6.18M
| $54.3K | ﹤0.01% |
49,800
+300
| +0.6% | +$335 |
|
|
PRPH
3384
DELISTED
ProPhase Labs
PRPH
| $54K | ﹤0.01% |
13,792
-16,189
| -54% | -$54.1K |
|
|
NVNO
3385
enVVeno Medical
NVNO
$7.08M
| $53.9K | ﹤0.01% |
+386
| New | +$45.6K |
|
|
TWAV
3386
TaoWeave Inc
TWAV
$4.49M
| $53.7K | ﹤0.01% |
+14,394
| New | +$46.1K |
|
|
ISPO
3387
DELISTED
Inspirato
ISPO
| $52.6K | ﹤0.01% |
+15,435
| New | +$56.7K |
|
3388
Stagwell
STGW
$2.07B
| $51.8K | ﹤0.01% |
+11,500
| New | +$57.8K |
|
3389
Rafael Holdings
RFL
$101M
| $51.6K | ﹤0.01% |
29,831
+1,103
| +4% | +$1.8K |
|
3390
ICZOOM Group
IZM
$3.24M
| $51.2K | ﹤0.01% |
+18,837
| New | +$41K |
|
3391
Sonoma Pharmaceuticals
SNOA
$5.26M
| $50.6K | ﹤0.01% |
+17,800
| New | +$53.8K |
|
3392
Opko Health
OPK
$985M
| $50.3K | ﹤0.01% |
+38,100
| New | +$52.1K |
|
|
DMRA
3393
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.78B
| $49.6K | ﹤0.01% |
14,544
-800
| -5% | -$2.37K |
|
|
FAT
3394
DELISTED
FAT Brands
FAT
| $49.5K | ﹤0.01% |
20,800
-1,300
| -6% | -$3.29K |
|
|
AACG
3395
ATA Creativity
AACG
$39.3M
| $49.3K | ﹤0.01% |
64,044
-400
| -0.6% | -$359 |
|
|
KNDI
3396
Kandi Technologies Group
KNDI
$67.5M
| $48.6K | ﹤0.01% |
43,800
-800
| -2% | -$934 |
|
3397
Smith Micro Software
SMSI
$14.5M
| $48.1K | ﹤0.01% |
11,168
-240
| -2% | -$1.07K |
|
|
TTNP
3398
DELISTED
Titan Pharmaceuticals
TTNP
| $47.8K | ﹤0.01% |
+11,380
| New | +$48.3K |
|
3399
OLB
OLB
$4.28M
| $47.2K | ﹤0.01% |
+25,260
| New | +$39.2K |
|
3400
Dyadic International
DYAI
$38.3M
| $47.1K | ﹤0.01% |
47,605
+16,629
| +54% | +$18.2K |
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.